Tumor-suppressive pathways in pancreatic carcinoma

Cancer Research

Volumn 57, Issue 9, 1997, Pages 1731-1734

  Rozenblum, Ester ^a   Schutte, Mieke ^a   Goggins, Michael ^a   Hahn, Stephan A ^a   Panzer, Shawn ^a   Zahurak, Marianna ^a   Goodman, Steven N ^a   Sohn, Taylor A ^a   Hruban, Ralph H ^a   Yeo, Charles J ^a   Kern, Scott E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P16; PROTEIN P53;

ADULT; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; ONCOGENE K RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BRCA2 PROTEIN; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HETEROZYGOTE; HUMANS; MALE; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; SEQUENCE DELETION; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 14444284330     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
2. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
3. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
4. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 385: 80-83, 1992.
5. Reifenberger, G., Liu, L., Ichimura, K. Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1996.
6. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
7. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
8. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., and Strauss, M. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
9. Kratzke, R. A., Greatens, T. M., Rubins, J. B., Maddaus, M. A., Niewoehner, D. E., Niehans, G. A., and Geradts, J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res., 56: 3415-3420, 1996.
10. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., and Bartek, J. The p16-cyclinD/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res., 56: 5475-5483, 1996.
11. Kinoshita, L., Dosaka-Akita, H., Mishina, T., Akie, K., Nishi, M., Hiroumi, H., Hommura, F., and Kawakami, Y. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferate activity. Cancer Res., 56: 5557-5562, 1996.
12. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-31, 1994.
13. Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R., Orlow, I., Lacombe, L., Ponce-Castaneda, V., Lianes, P., Latres, E., Skolnick, M., Cordon-Cardo, C., and Kamb, A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146: 1199-1206, 1995.
14. Redston, M. S., Caldas. C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., and Kern, S. E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res., 54: 3025-3033, 1994.
15. Hahn, S. A., Schutte, M., Hoque, A. T. M. S., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. DPC4, a candidate tumor suppressor gene at 18q21.1. Science (Washington DC), 271: 350-353, 1996.
16. Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., and Kern, S. E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res., 56: 5360-5364, 1996.
17. Durbec, J. P., Chevillotte, G., Bidart, J. M., Berthezene, P., and Sarles, H. Diet, alcohol, tobacco and risk of cancer of the pancreas: a case-control study. Br. J. Cancer, 47: 463-470, 1983.
18. Yeo, C. J., Cameron, J. L., Lillemoe, K. D., Sitzmann, J. V., Hruban, R. H., Goodman, S. N., Dooley, W. C., Coleman, J., and Pitt, H. A. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann. Surg., 221: 721-733, 1995.
19. Miller, D. G. On the nature of susceptibility to cancer. Cancer (Phila.), 46: 1307-1318, 1980.
20. Hahn, S. A., Seymour, A. B., Hoque, A. T. M. S., Schutte, M., da Costa, L. T., Redston, M. S., Caldas, C., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. Allelotype of pancreatic adenocarcinoma using a xenograft model. Cancer Res., 55: 4670-4675, 1995.
21. Huang, L., Lang. D., Geradts, J., Obara, T., Klein-Szanto, A. J., Lynch, H. T., and Ruggeri, B. A. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol. Carcinog., 15: 85-95, 1996.
22. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J-P. J., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.